Agenus to Advance Three Checkpoint Modulator Antibodies into Development MarketWatch We are encouraged to have identified high-quality agonist antibodies for this very competitive target, something that has proven difficult for many other companies,” said Robert B. Stein, MD, PhD, Chief Scientific Officer of Agenus. “Furthermore, it is ... Agenus reports net loss attributable to common stockholders of $5.8 million ... |
